Korro Bio Nominates KRRO-121 Candidate, Secures $85M Private Placement
Korro Bio nominated KRRO-121 for clinical development as a potential first-in-class therapy for hyperammonemia in urea cycle disorders and hepatic encephalopathy, targeting $1B+ market opportunities. It closed an $85 million oversubscribed private placement, extending cash runway into the second half of 2028 with $85.2 million in year-end funds.
1. KRRO-121 Nomination Targets Hyperammonemia
Korro Bio nominated KRRO-121 for clinical development to treat hyperammonemia in urea cycle disorders and hepatic encephalopathy. The RNA editing candidate aims to stabilize glutamine synthase via a GalNAc-conjugated delivery, offering potential pan-UCD treatment across subtypes and targeting markets exceeding $1 billion each.
2. Expanded R&D Pipeline and AATD Progress
The company advanced its GalNAc-conjugated AATD program after preclinical RNA editing exceeded 90% in vivo efficacy, demonstrating repeat dosing potential. Additional preclinical efforts include AMPKγ1 activation for longevity and a de novo TDP-43 variant for ALS, leveraging the OPERA® RNA editing platform.
3. $85M Financing Extends Cash Runway
On March 10, 2026, Korro closed an oversubscribed $85 million private placement led by healthcare investors. With $85.2 million in cash, cash equivalents and marketable securities at year-end, the financing secures operations into the second half of 2028.
4. Upcoming Milestones for 2026
Korro plans to nominate its GalNAc AATD development candidate in Q2 2026 and file regulatory submissions for KRRO-121 in H2 2026. A third GalNAc-conjugated candidate is also slated for nomination during the second half of 2026.